Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 21,205 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Terminated Phase 3 Interventional Results available

Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

NCT00500240
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Insulin Glargine, Insulin Aspart
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 23, 2026, 9:15 AM EDT
Terminated Phase 1 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

NCT03465540
View directory record Official record
Conditions
Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, AML, MDS, NHL
Interventions
AMG 397, Dexamethasone, Azacitidine
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults

NCT03478891
View directory record Official record
Conditions
Healthy Adult Immune Responses to Vaccine
Interventions
VRC-EBOMAB092-00-AB (MAb114)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Phase 1 Interventional

Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT00963274
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Bortezomib, Romidepsin
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Development of a Tailored HIV Prevention Intervention for Young Men

NCT02842060
View directory record Official record
Conditions
HIV Infections
Interventions
myDEx, NTHP
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 24 Years · Male only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.

NCT01625182
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
Fingolimod, Placebo Comparator
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
12
States / cities
Orange, California • Miami, Florida • St. Petersburg, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Oct 23, 2026, 9:15 AM EDT
Not listed No phase listed Observational

Evaluation of the MP Diagnostics HTLV Blot 2.4

NCT01467024
View directory record Official record
Conditions
HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2, HTLV I Associated T Cell Leukemia Lymphoma, HTLV I Associated Myelopathies
Interventions
CDPHL Algorithm
Other
Lead sponsor
MP Biomedicals, LLC
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Richmond, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 23, 2026, 9:15 AM EDT
Not listed Phase 1 Interventional

Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis

NCT00411723
View directory record Official record
Conditions
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting
Interventions
RTL1000 (recombinant T cell receptor ligand), RTL1000 Placebo
Drug
Lead sponsor
Artielle ImmunoTherapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2009 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Belimumab in Remission of VASculitis

NCT01663623
View directory record Official record
Conditions
Vasculitis
Interventions
Placebo, Belimumab 10 mg/kg, Azathioprine
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 23, 2026, 9:15 AM EDT
Terminated No phase listed Observational

Wearable Auscultation Device Validation in Children

NCT06112080
View directory record Official record
Conditions
Asthma, Asthma in Children, Wheezing, Pediatric Asthma
Interventions
RESP™ Biosensor
Device
Lead sponsor
Strados Labs, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
36 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of Closed-Loop Glucose Control in People With Type 1 Diabetes (BPK004)

NCT00977808
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed-Loop, Model Predictive Control (MPC), Open-Loop
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Phase 2 Interventional

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00014508
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
sargramostim, cyclophosphamide, cyclosporine, fludarabine phosphate, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Not applicable Interventional

Modification of Asthma With Soy Isoflavone

NCT00741208
View directory record Official record
Conditions
Asthma
Interventions
Soy Isoflavone
Dietary Supplement
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 23, 2026, 9:15 AM EDT
Terminated Not applicable Interventional

Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD)

NCT01964625
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
PET-CT Scan
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2013 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Phase 1 Interventional

Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma

NCT00000689
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, HIV Infections
Interventions
Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Methotrexate, Cytarabine, Leucovorin calcium, Sargramostim, Dexamethasone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acceptability, Feasibility and Preliminary Impact of OurPlan, an mHealth HIV Prevention Intervention for Male Couples

NCT04836091
View directory record Official record
Conditions
HIV/AIDS
Interventions
Waitlist, Intervention
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 23, 2026, 9:15 AM EDT
Recruiting Phase 4 Interventional

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

NCT06875960
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Interventions
BMS-986165
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Farmington, Connecticut • New York, New York • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Not applicable Interventional Results available

Comparison of Liquid Kaletra and Low Dose Kaletra Tablets

NCT00762320
View directory record Official record
Conditions
HIV Infections
Interventions
Low dose Kaletra tablets
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
3 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 23, 2026, 9:15 AM EDT
Withdrawn Phase 2 Interventional

Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes

NCT01477476
View directory record Official record
Conditions
Type I Diabetes
Interventions
Anakinra, Placebo Comparator
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 23, 2026, 9:15 AM EDT
Withdrawn Phase 1 Interventional

Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

NCT02800889
View directory record Official record
Conditions
Lymphoma, Solid Tumor (Excluding CNS)
Interventions
Pixantrone
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
6 Months to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Detection of Bovine and Soy Proteins in Human Milk

NCT04851340
View directory record Official record
Conditions
Microbiome, Stress, Food Allergy in Infants
Interventions
Cow's Milk, Soy Milk
Other
Lead sponsor
University of Idaho
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Moscow, Idaho
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Low-dose Fostemsavir Extended Release Relative Bioavailability Study

NCT04757974
View directory record Official record
Conditions
HIV Infections
Interventions
Fostemsavir 600 mg, Fostemsavir 200 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

NCT04021290
View directory record Official record
Conditions
HIV Infections
Interventions
DTG/3TC FDC, CAR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 23, 2026, 9:15 AM EDT
Completed Not applicable Interventional

SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir

NCT00002310
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Crofelemer
Drug
Lead sponsor
Shaman Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
San Francisco, California • Fort Lauderdale, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 9:15 AM EDT